HIGH FACTOR IX TROUGH LEVELS AT STEADY STATE

ADULT
PEDIATRIC
Mean steady-state Factor IX trough levels when dosed every 7 days Mean steady-state Factor IX trough levels when dosed every 14 days

*Only time points with ≥3 observations are plotted. Steady-state mean trough is calculated from all observations at any time point. The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.

VIEW PEDIATRIC DATA

High factor levels give this police officer the protection he needs

“It’s the peace of mind I get having high factor levels; especially in my day-to-day life.”

Watch John’s full story

EXTENDED HALF‑LIFE. EXTENDED TIME BETWEEN DOSES.

In the pivotal trial, IDELVION delivered a prolonged half‑life

  • In clinical trials, previous Factor IX products used by subjects had an average half‑life of 22 hours. Previous FIX products refers to plasma-derived FIX or rFIX3
  • Half‑life is based on a single dose of 50 IU/kg in adults (≥18 years)
HALF-LIFE 104 HOURS
Mean steady-state Factor IX trough levels when dosed every 7 days in patients <12 years of age

*The mean dose for pediatric patients receiving prophylaxis every 7 days was 47 IU/kg.

0 spontaneous bleeds

IDELVION is the only extended half‑life Factor IX therapy to deliver a zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials

VIEW EFFICACY DATA
MOA molecule - Recombinant IX fusion protein

IDELVION uses albumin fusion technology to extend half‑life with minimal risk of an immune response

SEE THE IDELVION MOA

References: 1. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 2. Data on file. Available from CSL Behring as DOF IDL-003. 3. Data on file. Available from CSL Behring as DOF IDL-001.

X
You are now leaving the current website.

Do you want to continue?